BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 25528312)

  • 1. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
    Wang SH; Chen DY; Lin YS; Mao CT; Tsai ML; Hsieh MJ; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    PLoS One; 2015; 10(6):e0131122. PubMed ID: 26115092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Su FC; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Cherng WJ; Chen TH
    Medicine (Baltimore); 2015 Jul; 94(28):e1128. PubMed ID: 26181549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction.
    Kawada T
    Int J Cardiol; 2016 Nov; 222():1072-1073. PubMed ID: 26427543
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study.
    Yang TY; Liaw YP; Huang JY; Chang HR; Chang KW; Ueng KC
    Acta Diabetol; 2016 Jun; 53(3):461-8. PubMed ID: 26687195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
    Liang CY; Chen DY; Mao CT; Hsieh IC; Hung MJ; Wang CH; Wen MS; Cherng WJ; Chen TH
    Medicine (Baltimore); 2018 Dec; 97(52):e13844. PubMed ID: 30593182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
    Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
    Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
    Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
    Scheen AJ; Paquot N
    Rev Med Liege; 2015 Oct; 70(10):511-6. PubMed ID: 26727841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
    Chan SY; Ou SM; Chen YT; Shih CJ
    Int J Cardiol; 2016 Sep; 218():170-175. PubMed ID: 27236110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
    Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
    Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
    PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
    JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
    Wang MT; Lin SC; Tang PL; Hung WT; Cheng CC; Yang JS; Chang HT; Liu CP; Mar GY; Huang WC
    Cardiovasc Diabetol; 2017 Jul; 16(1):89. PubMed ID: 28697774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
    Weir DL; McAlister FA; Senthilselvan A; Minhas-Sandhu JK; Eurich DT
    JACC Heart Fail; 2014 Dec; 2(6):573-82. PubMed ID: 24998080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.